The Intercepting Blood Cancers (IBC) 2024 hybrid workshop will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:
- Monoclonal B lymphocytosis (MBL), chronic lymphocytic leukemia (CLL) and low-grade lymphoma
- Myelodysplastic syndromes (MDS), clonal hematopoiesis of indeterminate potential (CHIP) and acute myeloid leukemia (AML)
- Multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS)
The current aims of the meeting are to:
- Describe current knowledge of blood cancer precursors and how these might enable early clinical intervention
- Discuss ongoing clinical studies and any available data from these on treatment interceptions for early-stage blood cancers
- Share knowledge and clinical insights between blood cancer disciplines and therapy areas
- Plan for publication and dissemination of consensus findings from discussions across each of the key topic tracks
